Chemotherapy response test from AntiCancer:
This article was originally published in Clinica
AntiCancer (US) has received a notice of allowance for a US patent for its histoculture drug response assay (HDRA) for chemotherapy. The test enables oncologists to select the appropriate agent within 72 hours of tissue culture in the laboratory. Alternatively, if HDRA indicates that no chemotherapy will be effective, the patient may elect not to undergo treatment. AntiCancer provides the testing service at its San Diego, California, facility.